Ergotamine

# Ergotamine ## Overview - **Classification**: Ergot alkaloid. - **Mechanism**: Partial agonist/antagonist at alpha-adrenergic, serotonergic (5-HT1B/1D), and dopaminergic receptors. Causes potent cerebral and peripheral vasoconstriction. ## Primary Indications 1. **Acute Migraine Attacks** - Relief of moderate to severe migraine pain. 2. **Cluster Headaches** - Used for acute treatment, often when other options fail. ## Adult Dosing ### Standard Dosing **Acute Migraine/Cluster Headache (Oral, often combined with caffeine)** - **Dose**: **2 mg** - **Frequency**: At first sign of attack, then **1 mg** every 30 minutes if needed. - **Route**: Oral - **Maximum Dose**: **6 mg** per attack. - **Maximum Weekly Dose**: **10 mg** in any 7-day period. **Acute Migraine/Cluster Headache (Rectal Suppository)** - **Dose**: **2 mg** - **Frequency**: At first sign of attack, then **2 mg** in 1 hour if needed. - **Route**: Rectal - **Maximum Dose**: **4 mg** per attack. - **Maximum Weekly Dose**: **10 mg** in any 7-day period. ### Dose Adjustments - **Renal Impairment**: **Contraindicated** in severe renal impairment due to accumulation risk. Use with extreme caution in mild-moderate. - **Hepatic Impairment**: **Contraindicated** in severe hepatic impairment due to impaired metabolism. Use with extreme caution in mild-moderate. - **Elderly Patients**: Use with extreme caution; generally **not recommended** due to increased risk of adverse effects (e.g., peripheral vasoconstriction). ## Pediatric Dosing Ergotamine is generally **NOT RECOMMENDED** for pediatric patients due to the risk of serious adverse effects (e.g., ergotism, peripheral ischemia) and the availability of safer, more effective acute migraine treatments. There is no established safe and effective pediatric dosing. ### Neonates (0-28 days) - **Not Recommended**: Due to significant safety concerns and lack of efficacy data. ### Infants (1-12 months) - **Not Recommended**: Due to significant safety concerns and lack of efficacy data. ### Children (1-12 years) - **Not Recommended**: Due to significant safety concerns and lack of efficacy data. ### Adolescents (13-18 years) - **Not Recommended**: Though some older literature may exist, current guidelines favor other agents. If used, follow adult max dose and monitor closely. ## Safety Information ### Contraindications - **Absolute**: Pregnancy, lactation, peripheral vascular disease, coronary heart disease, uncontrolled hypertension, severe hepatic/renal impairment. - **Absolute**: Sepsis, temporal arteritis, severe pruritus. - **Absolute**: Concomitant use with potent CYP3A4 inhibitors (e.g., macrolide antibiotics, protease inhibitors, azole antifungals). ### Common Adverse Effects - **Common (1-10%)**: Nausea, vomiting, abdominal pain, diarrhea. - **Common (1-10%)**: Muscle pain/cramps, weakness, numbness, tingling in fingers/toes. - **Serious but Rare**: Ergotism (vasoconstriction leading to ischemia, gangrene), myocardial infarction, stroke, fibrotic complications (pleural, retroperitoneal, cardiac valve fibrosis). ### Key Drug Interactions - **Potent CYP3A4 inhibitors (e.g., erythromycin, clarithromycin, ritonavir, ketoconazole, itraconazole)**: **CONTRAINDICATED**. Greatly increases ergotamine levels, leading to severe vasoconstriction (ergotism). - **Triptans (e.g., sumatriptan, zolmitriptan)**: Increased risk of prolonged vasoconstriction. **Separate administration by at least 24 hours**. - **Beta-blockers**: Increased peripheral vasoconstriction risk. Monitor for signs of ischemia. - **Nicotine**: May exacerbate vasoconstriction. ## Monitoring & Follow-up - **Before Treatment**: Assess cardiovascular history (CAD, PVD), BP, hepatic/renal function. Rule out pregnancy. - **During Treatment**: Monitor for signs of ergotism (cold, pale, painful extremities, paresthesias). Monitor blood pressure. - **Clinical Signs**: Instruct patient to immediately report persistent numbness, tingling, pain in extremities, chest pain, or leg weakness. ## Clinical Pearls - 💡 **Tip 1**: Ergotamine is most effective when taken at the **earliest sign** of a migraine or cluster headache. - 💡 **Tip 2**: **Strictly adhere to maximum dose limits** (per attack and per week) to prevent ergotism. Overuse can lead to drug-induced headaches. - 💡 **Tip 3**: **Avoid in patients with cardiovascular disease**, uncontrolled hypertension, or risk factors for vasoconstrictive events. - 💡 **Tip 4**: Advise patients about the **severe drug interaction with CYP3A4 inhibitors** and the need to avoid them. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.